SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Dicerna Pharmaceuticals Announces That Kyowa Hakko Kirin Has Selected a Second DsiRNA Therapeutic Candidate for Development, Triggering $5 Million Milestone Payment